MARKER THERAPEUTICS, INC. Increase (Decrease) in Due to Related Parties, Current
MARKER THERAPEUTICS, INC. (MRKR) reported Increase (Decrease) in Due to Related Parties, Current of $804.79 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent · last filed 2026-08-14
- MARKER THERAPEUTICS, INC. increase (decrease) in due to related parties, current for the quarter ending 2026-06-30 was -$196.43K, a 180.08% decline year-over-year.
- MARKER THERAPEUTICS, INC. increase (decrease) in due to related parties, current for the quarter ending 2026-03-31 was $1.00M.
- MARKER THERAPEUTICS, INC. increase (decrease) in due to related parties, current for the quarter ending 2025-12-31 was -$328.31K, a 140.68% decline year-over-year.
- MARKER THERAPEUTICS, INC. increase (decrease) in due to related parties, current for the quarter ending 2025-09-30 was -$328.32K, a 153.75% decline year-over-year.
- MARKER THERAPEUTICS, INC. increase (decrease) in due to related parties, current for fiscal 2025 was -$1.71M, a 549.13% decline from fiscal 2024.
- MARKER THERAPEUTICS, INC. increase (decrease) in due to related parties, current for fiscal 2024 was $380.85K, a 71.36% decline from fiscal 2023.
- MARKER THERAPEUTICS, INC. increase (decrease) in due to related parties, current for fiscal 2023 was $1.33M, a 46.81% decline from fiscal 2022.
- MARKER THERAPEUTICS, INC. increase (decrease) in due to related parties, current for fiscal 2022 was $2.50M.
| Period end | Increase (Decrease) in Due to Related Parties, Current 3 month | Increase (Decrease) in Due to Related Parties, Current 6 month | Increase (Decrease) in Due to Related Parties, Current 9 month | Increase (Decrease) in Due to Related Parties, Current 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$196.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $804.79K 10-Q · filed 2026-08-14 | $476.48K derived: sum of 3 quarters · filed 2026-08-14 | $148.16K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.00M 10-Q · filed 2026-05-15 | $672.91K derived: sum of 2 quarters · filed 2026-05-15 | $344.60K derived: sum of 3 quarters · filed 2026-05-15 | $589.90K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$328.31K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$656.63K derived: sum of 2 quarters · filed 2026-03-18 | -$411.33K derived: sum of 3 quarters · filed 2026-08-14 | -$1.71M 10-K · filed 2026-03-18 |
| 2025-09-30 | -$328.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$83.01K derived: sum of 2 quarters · filed 2026-08-14 | -$1.38M 10-Q · filed 2025-11-13 | -$575.12K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $245.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.05M 10-Q · filed 2026-08-14 | -$246.81K derived: sum of 3 quarters · filed 2026-08-14 | $364.06K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$1.30M 10-Q · filed 2026-05-15 | -$492.11K derived: sum of 2 quarters · filed 2026-05-15 | $118.76K derived: sum of 3 quarters · filed 2026-05-15 | $57.36K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $807.06K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $1.42M derived: sum of 2 quarters · filed 2026-03-18 | $1.36M derived: sum of 3 quarters · filed 2026-03-18 | $380.85K 10-K · filed 2026-03-18 |
| 2024-09-30 | $610.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $549.47K derived: sum of 2 quarters · filed 2025-11-13 | -$426.22K 10-Q · filed 2025-11-13 | $535.52K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$61.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$1.04M 10-Q · filed 2025-08-14 | -$75.35K derived: sum of 3 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$975.69K 10-Q · filed 2025-05-15 | -$13.95K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $961.74K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.33M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $367.92K 10-Q · filed 2024-11-14 | |||
| 2023-03-31 | -$2.50M 10-Q · filed 2023-05-15 | -$5.05M derived: sum of 2 quarters · filed 2023-05-15 | -$8.00M derived: sum of 3 quarters · filed 2023-05-15 | |
| 2022-12-31 | -$2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$5.50M derived: sum of 2 quarters · filed 2023-03-22 | $2.50M 10-K · filed 2023-03-22 | |
| 2022-09-30 | -$2.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $5.05M 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $8.00M 10-Q · filed 2022-08-11 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 | |||
| 2014-12-31 | $369.00K 10-K · filed 2015-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |